X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

Content Team by Content Team
2nd November 2022
in Drug Development, News

One of the most difficult medical research findings, drug distribution still faces a lot of challenges, including surviving the acidic parts of the stomach, digestive enzymes, and most significantly, the mucus barrier that surrounds the digestive canal. Scientists at the Massachusetts Institute of Technology (MIT) have discovered a fresh approach.

They have created a robotic pill that might be used to orally distribute large protein medications like insulin, which are currently only available as injections and are made of protein or nucleic acids. The RoboCap, created by MIT, has a robotic cap that, once it enters the small intestine, burrows through the mucus layer, allowing the drugs to reach the cells lining the intestine.

In a report published in Science Robotics, Shriya Srinivasan, a research associate at MIT’s Koch Institute for Integrative Cancer Research, provided a thorough description of the pill.

Researchers have demonstrated that the innovative pills are capable of transporting both insulin and the antibiotic peptide vancomycin, which is currently given intravenously. The protective capsule was created by a team to navigate obstacles inside the body by rotating and tunnelling.

She reasoned that they could directly apply the medication to the epithelium if they could burrow through the mucus. According to a statement from Shriya Srinivasan, the concept is to swallow this capsule, allowing the outer layer to disintegrate in the digestive tract and expose all of the components that start to disintegrate and remove the mucus. The pill is about the size of a multivitamin and has a spinning mechanism on one end and the medication in a small reservoir on the other. The capsule’s gelatinous outer layer can be adjusted such that it dissolves only at a certain pH.

The RoboCap temporarily removes the primary mucous barrier before increasing local medication dispersion to improve absorption. The ability to create the ideal environment for the medicine to be absorbed is actually maximised by integrating all of these factors, according to Giovanni Traverso, a specialist in the area.

The RoboCap capsule is coated with tiny studs to brush the mucus away, and as the capsule dissolves, researchers claim that the change in pH causes a tiny engine inside the RoboCap capsule to start spinning. The medicine is slowly discharged into the digestive system thanks to the spinning motion’s aid in eroding the compartment where it is stored.

The team found that the robotic pill could deliver 20 to 40 times more medication than a similar capsule without the tunnelling mechanism when they tried it on animals to deliver both insulin or vancomycin. There haven’t been any negative effects reported yet after the medicine is freed from the capsule and it moves naturally through the digestive system. The team is optimistic that by altering the pH at which the gelatin covering dissolves, it may also be used to address the stomach or colon.

Previous Post

Energy Crises May Impair European Medicine Supply Lines

Next Post

Wall Street Cautiously Optimistic After Gene Therapy Deals

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
Next Post
Wall Street Cautiously Optimistic After Gene Therapy Deals

Wall Street Cautiously Optimistic After Gene Therapy Deals

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In